Orencia (abatacept) Document Number: MODA-0091

Size: px
Start display at page:

Download "Orencia (abatacept) Document Number: MODA-0091"

Transcription

1 Orencia (abatacept) Dcument Number: MODA-0091 Last Review Date: 09/19/2017 Date f Origin: 07/02/2010 Dates Reviewed: 07/2010, 09/2010, 12/2010, 02/15/11, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/12, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 3/2014, 06/2014, 09/2014, 12/2014, 03/2015, 06/2015, 9/2015, 12/2015, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 04/2017, 06/2017, 08/2017, 09/2017 I. Length f Authrizatin Cverage will be prvided fr 6 mnths and may be renewed. II. Dsing Limits A. Quantity Limit (max daily dse) [Pharmacy Benefit]: Orencia ClickJect 125 mg autinjectr: 4 syringes per 28 days Orencia 250 mg vials: Lading: 4 vials (1000 mg) at weeks 0, 2 & 4 Maintenance: 4 vials (1000 mg) per 28 days Orencia prefilled syringes (50 mg, 87.5 mg, r 125 mg): 4 syringes per 28 days B. Max Units (per dse and ver time) [Medical Benefit]: IV Frmulatin: Lading: 100 billable units at weeks 0, 2, & 4 Maintenance: 100 billable units per 4 weeks Subcutaneus frmulatin: III. 13 billable units (1 dse) every week Initial Apprval Criteria Site f care specialty infusin prgram requirements are met (refer t Mda Site f Care Plicy). Cverage is prvided in the fllwing cnditins: Patient is nt receiving cmbinatin therapy with TNF antagnists r ther bilgic respnse mdifier; AND Patient has been evaluated and screened fr the presence f latent TB infectin prir t initiating treatment; AND Patient has been evaluated and screened fr the presence f hepatitis B virus (HBV) prir t initiating treatment; AND Mda Health Plan, Inc. Medical Necessity Criteria Page 1/14

2 Patient des nt have an active infectin, including clinically imprtant lcalized infectins; AND Must nt be administered cncurrently with live vaccines; AND Rheumatid Arthritis (RA) Adult patient (18 years r lder); AND Dcumented mderate t severe active disease; AND Patient has had at least a 3 mnth trial and failure f previus therapy with ONE ral disease mdifying anti-rheumatic agent (DMARD) such as methtrexate, azathiprine, auranfin, hydrxychlrquine, penicillamine, sulfasalazine, r leflunmide; AND May be used as a single agent r in cmbinatin with ther DMARDS including methtrexate(mtx), unless cntraindicated Patient must try and have an inadequate respnse, cntraindicatin, r intlerance t at least a three (3) mnth trial f Enbrel AND Humira; OR Patient is cntinuing treatment Plyarticular Juvenile Idipathic Arthritis (pjia) Patient is age 2 r greater; AND Dcumented mderate t severe active plyarticular disease; AND Patient has had at least a 1 mnth trial and failure (unless cntraindicated r intlerant) f previus therapy with either ral nn-steridal anti-inflammatry drugs (NSAIDs) OR a systemic gluccrticid (prednisne, methylprednislne, etc.); AND May be used as single agent r in cmbinatin with methtrexate unless cntraindicated Patient must try and have an inadequate respnse, cntraindicatin, r intlerance t at least a three (3) mnth trial f Enbrel AND Humira; OR Patient is cntinuing treatment Psriatic Arthritis (PsA) Adult patient (18 years r lder); AND Dcumented mderate t severe active disease; AND Fr patients with predminantly axial disease OR active enthesitis and/r dactylitis, an adequate trial and failure f at least TWO (2) nn-steridal anti-inflammatry agents (NSAIDs), unless use is cntraindicated; OR Fr patients with peripheral arthritis, a trial and failure f at least a 3 mnth trial f ONE ral disease-mdifying anti-rheumatic agent (DMARD) such as methtrexate, azathiprine, sulfasalazine, r hydrxychlrquine Patient must try and have an inadequate respnse, cntraindicatin, r intlerance t at least a three (3) mnth trial f Enbrel AND Humira; OR Patient is cntinuing treatment FDA Apprved Indicatin(s) Mda Health Plan, Inc. Medical Necessity Criteria Page 2/14

3 IV. Renewal Criteria Cverage can be renewed based upn the fllwing criteria: Patient cntinues t meet criteria identified in sectin III; AND Disease respnse as indicated by imprvement in signs and symptms cmpared t baseline such as the number f tender and swllen jint cunts; AND Absence f unacceptable txicity frm the drug. Examples f unacceptable txicity include the fllwing: serius infectins, respiratry adverse events in thse with predispsing cnditins, etc.; AND Patient is receiving nging mnitring fr presence f TB r ther active infectins V. Dsage/Administratin Indicatin Rheumatid Arthritis and Psriatic Arthritis in adults Dse Intravenus Dsing Weight < 60kg: 500 mg at weeks 0, 2, & 4, then every 4 weeks thereafter Weight 60 t 100 kg: 750 mg at weeks 0, 2, & 4, then every 4 weeks thereafter Weight > 100 kg: 1,000 mg at weeks 0, 2, & 4, then every 4 weeks thereafter Subcutaneus Dsing (Orencia 125 mg Subcutaneus Injectin ONLY) Administer by subcutaneus injectin nce weekly May initiate with r withut an IV lading dse If initiated with an IV lading dse, a single weight-based infusin (see abve) shuld be fllwed by the first 125 mg subcutaneus injectin within a day Patients transitining frm ORENCIA intravenus therapy t subcutaneus administratin shuld administer the first subcutaneus dse instead f the next scheduled intravenus dse. Intravenus Dsing (patients aged 6 years r lder ONLY) Plyarticular Juvenile Idipathic Arthritis Weight < 75 kg: 10 mg/kg at weeks 0, 2, & 4, then every 4 weeks thereafter Weight 75 t 100 kg: 750 mg at weeks 0, 2, & 4, then every 4 weeks thereafter Weight > 100 kg: 1,000 mg at weeks 0, 2, & 4, then every 4 weeks thereafter Subcutaneus Dsing using prefilled syringes (patients aged 2 years r lder) Weight 10 t < 25 kg: 50 mg weekly Weight 25 t < 50 kg: 87.5 mg weekly Weight 50 kg: 125 mg weekly Mda Health Plan, Inc. Medical Necessity Criteria Page 3/14

4 VI. Billing Cde/Availability Infrmatin JCde: J0129 Injectin, Abatacept, 10 mg; 1 billable unit = 10mg (Cde may be used fr Medicare when drug administered under the direct supervisin f a physician, nt fr use when drug is self-administered) NDC: Orencia 250 mg 15 ml vial: xx Orencia ClickJect 125 mg/ml Autinjectr and prefilled syringe: xx Orencia prefilled syringe 50 mg/0.4 ml: xx Orencia prefilled syringe 87.5 mg/0.7 ml: xx VII. References 1. Orencia [package insert]. Princetn, NJ; Bristl-Myers Squibb; June Accessed August Singh JA, Saag KG, Bridges SL Jr, et al American Cllege f Rheumatlgy Guideline fr the Treatment f Rheumatid Arthritis. Arthritis Care Res (Hbken) Nv 6. di: /acr Natinal Institute fr Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, rituximab and abatacept fr the treatment f rheumatid arthritis after the failure f a TNF inhibitr. Lndn (UK): Natinal Institute fr Health and Clinical Excellence (NICE); 2010 Aug. 73 p. (Technlgy appraisal guidance; n. 195) 4. Beukelman T, Patkar NM, Saag KG, et al American Cllege f Rheumatlgy recmmendatins fr the treatment f juvenile idipathic arthritis: initiatin and safety mnitring f therapeutic agents fr the treatment f arthritis and systemic features. Arthritis Care Res (Hbken) Apr;63(4): Ringld S, Weiss PF, Beukelman T, et al update f the 2011 American Cllege f Rheumatlgy recmmendatins fr the treatment f juvenile idipathic arthritis: recmmendatins fr the medical therapy f children with systemic juvenile idipathic arthritis and tuberculsis screening amng children receiving bilgic medicatins. Arthritis Rheum Oct;65(10): DeWitt EM, Kimura Y, Beukelman T, et al. Cnsensus treatment plans fr new-nset systemic juvenile idipathic arthritis. Arthritis Care Res (Hbken) Jul;64(7): Gttlieb A, Krman NJ, Grdn KB, Feldman SR, Lebwhl M, K JY, Van Vrhees AS, Elmets CA, Lenardi CL, Beutner KR, Bhushan R, Menter A. Guidelines f care fr the management f psriasis and psriatic arthritis: Sectin 2. Psriatic arthritis: verview and guidelines f care fr treatment with an emphasis n the bilgics. J Am Acad Dermatl 2008 May;58(5): Gssec L, Smlen JS, Ramir S, et al. Eurpean League Against Rheumatism (EULAR) recmmendatins fr the management f psriatic arthritis with pharmaclgical therapies: 2015 update. Ann Rheum Dis Dec 7. pii: annrheumdis di: /annrheumdis Smlen JS, Landewe R, Bijilsma J, et al. EULAR recmmendatins fr the management f rheumatid arthritis with synthetic and bilgical disease-mdifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76: Mda Health Plan, Inc. Medical Necessity Criteria Page 4/14

5 10. First Cast Service Optins, Inc. Lcal Cverage Determinatin (LCD): Abatacept (L33257). Centers fr Medicare & Medicaid Services, Inc. Updated n 07/01/2014 with effective date 10/01/2015. Accessed August Wiscnsin Physicians Service Insurance Crpratin. Lcal Cverage Determinatin (LCD): Drugs and Bilgics (Nn-chemtherapy) (L34741). Centers fr Medicare & Medicaid Services, Inc. Updated n 06/21/2017 with effective date 07/01/2017. Accessed August Appendix 1 Cvered Diagnsis Cdes ICD-10 L40.50 Arthrpathic psriasis, unspecified L40.51 Distal interphalangeal psriatic arthrpathy L40.52 Psriatic arthritis mutilans L40.53 Psriatic spndylitis L40.59 Other psriatic arthrpathy M05.10 Rheumatid lung disease with rheumatid arthritis f unspecified site M Rheumatid lung disease with rheumatid arthritis f right shulder M Rheumatid lung disease with rheumatid arthritis f left shulder M Rheumatid lung disease with rheumatid arthritis f unspecified shulder M Rheumatid lung disease with rheumatid arthritis f right elbw M Rheumatid lung disease with rheumatid arthritis f left elbw M Rheumatid lung disease with rheumatid arthritis f unspecified elbw M Rheumatid lung disease with rheumatid arthritis f right wrist M Rheumatid lung disease with rheumatid arthritis f left wrist M Rheumatid lung disease with rheumatid arthritis f unspecified wrist M Rheumatid lung disease with rheumatid arthritis f right hand M Rheumatid lung disease with rheumatid arthritis f left hand M Rheumatid lung disease with rheumatid arthritis f unspecified hand M Rheumatid lung disease with rheumatid arthritis f right hip M Rheumatid lung disease with rheumatid arthritis f left hip M Rheumatid lung disease with rheumatid arthritis f unspecified hip M Rheumatid lung disease with rheumatid arthritis f right knee M Rheumatid lung disease with rheumatid arthritis f left knee M Rheumatid lung disease with rheumatid arthritis f unspecified knee M Rheumatid lung disease with rheumatid arthritis f right ankle and ft M Rheumatid lung disease with rheumatid arthritis f left ankle and ft M Rheumatid lung disease with rheumatid arthritis f unspecified ankle and ft M05.19 Rheumatid lung disease with rheumatid arthritis f multiple sites M05.20 Rheumatid vasculitis with rheumatid arthritis f unspecified site M Rheumatid vasculitis with rheumatid arthritis f right shulder M Rheumatid vasculitis with rheumatid arthritis f left shulder M Rheumatid vasculitis with rheumatid arthritis f unspecified shulder M Rheumatid vasculitis with rheumatid arthritis f right elbw Mda Health Plan, Inc. Medical Necessity Criteria Page 5/14

6 M Rheumatid vasculitis with rheumatid arthritis f left elbw M Rheumatid vasculitis with rheumatid arthritis f unspecified elbw M Rheumatid vasculitis with rheumatid arthritis f right wrist M Rheumatid vasculitis with rheumatid arthritis f left wrist M Rheumatid vasculitis with rheumatid arthritis f unspecified wrist M Rheumatid vasculitis with rheumatid arthritis f right hand M Rheumatid vasculitis with rheumatid arthritis f left hand M Rheumatid vasculitis with rheumatid arthritis f unspecified hand M Rheumatid vasculitis with rheumatid arthritis f right hip M Rheumatid vasculitis with rheumatid arthritis f left hip M Rheumatid vasculitis with rheumatid arthritis f unspecified hip M Rheumatid vasculitis with rheumatid arthritis f right knee M Rheumatid vasculitis with rheumatid arthritis f left knee M Rheumatid vasculitis with rheumatid arthritis f unspecified knee M Rheumatid vasculitis with rheumatid arthritis f right ankle and ft M Rheumatid vasculitis with rheumatid arthritis f left ankle and ft M Rheumatid vasculitis with rheumatid arthritis f unspecified ankle and ft M05.29 Rheumatid vasculitis with rheumatid arthritis f multiple sites M05.30 Rheumatid heart disease with rheumatid arthritis f unspecified site M Rheumatid heart disease with rheumatid arthritis f right shulder M Rheumatid heart disease with rheumatid arthritis f left shulder M Rheumatid heart disease with rheumatid arthritis f unspecified shulder M Rheumatid heart disease with rheumatid arthritis f right elbw M Rheumatid heart disease with rheumatid arthritis f left elbw M Rheumatid heart disease with rheumatid arthritis f unspecified elbw M Rheumatid heart disease with rheumatid arthritis f right wrist M Rheumatid heart disease with rheumatid arthritis f left wrist M Rheumatid heart disease with rheumatid arthritis f unspecified wrist M Rheumatid heart disease with rheumatid arthritis f right hand M Rheumatid heart disease with rheumatid arthritis f left hand M Rheumatid heart disease with rheumatid arthritis f unspecified hand M Rheumatid heart disease with rheumatid arthritis f right hip M Rheumatid heart disease with rheumatid arthritis f left hip M Rheumatid heart disease with rheumatid arthritis f unspecified hip M Rheumatid heart disease with rheumatid arthritis f right knee M Rheumatid heart disease with rheumatid arthritis f left knee M Rheumatid heart disease with rheumatid arthritis f unspecified knee M Rheumatid heart disease with rheumatid arthritis f right ankle and ft M Rheumatid heart disease with rheumatid arthritis f left ankle and ft M Rheumatid heart disease with rheumatid arthritis f unspecified ankle and ft M05.39 Rheumatid heart disease with rheumatid arthritis f multiple sites Mda Health Plan, Inc. Medical Necessity Criteria Page 6/14

7 M05.40 Rheumatid mypathy with rheumatid arthritis f unspecified site M Rheumatid mypathy with rheumatid arthritis f right shulder M Rheumatid mypathy with rheumatid arthritis f left shulder M Rheumatid mypathy with rheumatid arthritis f unspecified shulder M Rheumatid mypathy with rheumatid arthritis f right elbw M Rheumatid mypathy with rheumatid arthritis f left elbw M Rheumatid mypathy with rheumatid arthritis f unspecified elbw M Rheumatid mypathy with rheumatid arthritis f right wrist M Rheumatid mypathy with rheumatid arthritis f left wrist M Rheumatid mypathy with rheumatid arthritis f unspecified wrist M Rheumatid mypathy with rheumatid arthritis f right hand M Rheumatid mypathy with rheumatid arthritis f left hand M Rheumatid mypathy with rheumatid arthritis f unspecified hand M Rheumatid mypathy with rheumatid arthritis f right hip M Rheumatid mypathy with rheumatid arthritis f left hip M Rheumatid mypathy with rheumatid arthritis f unspecified hip M Rheumatid mypathy with rheumatid arthritis f right knee M Rheumatid mypathy with rheumatid arthritis f left knee M Rheumatid mypathy with rheumatid arthritis f unspecified knee M Rheumatid mypathy with rheumatid arthritis f right ankle and ft M Rheumatid mypathy with rheumatid arthritis f left ankle and ft M Rheumatid mypathy with rheumatid arthritis f unspecified ankle and ft M05.49 Rheumatid mypathy with rheumatid arthritis f multiple sites M05.50 Rheumatid plyneurpathy with rheumatid arthritis f unspecified site M Rheumatid plyneurpathy with rheumatid arthritis f right shulder M Rheumatid plyneurpathy with rheumatid arthritis f left shulder M Rheumatid plyneurpathy with rheumatid arthritis f unspecified shulder M Rheumatid plyneurpathy with rheumatid arthritis f right elbw M Rheumatid plyneurpathy with rheumatid arthritis f left elbw M Rheumatid plyneurpathy with rheumatid arthritis f unspecified elbw M Rheumatid plyneurpathy with rheumatid arthritis f right wrist M Rheumatid plyneurpathy with rheumatid arthritis f left wrist M Rheumatid plyneurpathy with rheumatid arthritis f unspecified wrist M Rheumatid plyneurpathy with rheumatid arthritis f right hand M Rheumatid plyneurpathy with rheumatid arthritis f left hand M Rheumatid plyneurpathy with rheumatid arthritis f unspecified hand M Rheumatid plyneurpathy with rheumatid arthritis f right hip M Rheumatid plyneurpathy with rheumatid arthritis f left hip M Rheumatid plyneurpathy with rheumatid arthritis f unspecified hip M Rheumatid plyneurpathy with rheumatid arthritis f right knee M Rheumatid plyneurpathy with rheumatid arthritis f left knee Mda Health Plan, Inc. Medical Necessity Criteria Page 7/14

8 M Rheumatid plyneurpathy with rheumatid arthritis f unspecified knee M Rheumatid plyneurpathy with rheumatid arthritis f right ankle and ft M Rheumatid plyneurpathy with rheumatid arthritis f left ankle and ft M Rheumatid plyneurpathy with rheumatid arthritis f unspecified ankle and ft M05.59 Rheumatid plyneurpathy with rheumatid arthritis f multiple sites M05.60 Rheumatid arthritis f unspecified site with f ther rgans and systems M Rheumatid arthritis f right shulder with f ther rgans and systems M Rheumatid arthritis f left shulder with f ther rgans and systems M Rheumatid arthritis f unspecified shulder with f ther rgans and systems M Rheumatid arthritis f right elbw with f ther rgans and systems M Rheumatid arthritis f left elbw with f ther rgans and systems M Rheumatid arthritis f unspecified elbw with f ther rgans and systems M Rheumatid arthritis f right wrist with f ther rgans and systems M Rheumatid arthritis f left wrist with f ther rgans and systems M Rheumatid arthritis f unspecified wrist with f ther rgans and systems M Rheumatid arthritis f right hand with f ther rgans and systems M Rheumatid arthritis f left hand with f ther rgans and systems M Rheumatid arthritis f unspecified hand with f ther rgans and systems M Rheumatid arthritis f right hip with f ther rgans and systems M Rheumatid arthritis f left hip with f ther rgans and systems M Rheumatid arthritis f unspecified hip with f ther rgans and systems M Rheumatid arthritis f right knee with f ther rgans and systems M Rheumatid arthritis f left knee with f ther rgans and systems M Rheumatid arthritis f unspecified knee with f ther rgans and systems M Rheumatid arthritis f right ankle and ft with f ther rgans and systems M Rheumatid arthritis f left ankle and ft with f ther rgans and systems M Rheumatid arthritis f unspecified ankle and ft with f ther rgans and systems M05.69 Rheumatid arthritis f multiple sites with f ther rgans and systems M05.70 Rheumatid arthritis with rheumatid factr f unspecified site withut rgan r systems M Rheumatid arthritis with rheumatid factr f right shulder withut rgan r systems M Rheumatid arthritis with rheumatid factr f left shulder withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified shulder withut rgan r systems M Rheumatid arthritis with rheumatid factr f right elbw withut rgan r systems M Rheumatid arthritis with rheumatid factr f left elbw withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified elbw withut rgan r systems M Rheumatid arthritis with rheumatid factr f right wrist withut rgan r systems M Rheumatid arthritis with rheumatid factr f left wrist withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified wrist withut rgan r systems Mda Health Plan, Inc. Medical Necessity Criteria Page 8/14

9 M Rheumatid arthritis with rheumatid factr f right hand withut rgan r systems M Rheumatid arthritis with rheumatid factr f left hand withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified hand withut rgan r systems M Rheumatid arthritis with rheumatid factr f right hip withut rgan r systems M Rheumatid arthritis with rheumatid factr f left hip withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified hip withut rgan r systems M Rheumatid arthritis with rheumatid factr f right knee withut rgan r systems M Rheumatid arthritis with rheumatid factr f left knee withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified knee withut rgan r systems M Rheumatid arthritis with rheumatid factr f right ankle and ft withut rgan r systems M Rheumatid arthritis with rheumatid factr f left ankle and ft withut rgan r systems M Rheumatid arthritis with rheumatid factr f unspecified ankle and ft withut rgan r systems M05.79 Rheumatid arthritis with rheumatid factr f multiple sites withut rgan r systems M05.80 Other rheumatid arthritis with rheumatid factr f unspecified site M Other rheumatid arthritis with rheumatid factr f right shulder M Other rheumatid arthritis with rheumatid factr f left shulder M Other rheumatid arthritis with rheumatid factr f unspecified shulder M Other rheumatid arthritis with rheumatid factr f right elbw M Other rheumatid arthritis with rheumatid factr f left elbw M Other rheumatid arthritis with rheumatid factr f unspecified elbw M Other rheumatid arthritis with rheumatid factr f right wrist M Other rheumatid arthritis with rheumatid factr f left wrist M Other rheumatid arthritis with rheumatid factr f unspecified wrist M Other rheumatid arthritis with rheumatid factr f right hand M Other rheumatid arthritis with rheumatid factr f left hand M Other rheumatid arthritis with rheumatid factr f unspecified hand M Other rheumatid arthritis with rheumatid factr f right hip M Other rheumatid arthritis with rheumatid factr f left hip M Other rheumatid arthritis with rheumatid factr f unspecified hip M Other rheumatid arthritis with rheumatid factr f right knee M Other rheumatid arthritis with rheumatid factr f left knee M Other rheumatid arthritis with rheumatid factr f unspecified knee M Other rheumatid arthritis with rheumatid factr f right ankle and ft M Other rheumatid arthritis with rheumatid factr f left ankle and ft M Other rheumatid arthritis with rheumatid factr f unspecified ankle and ft M05.89 Other rheumatid arthritis with rheumatid factr f multiple sites Mda Health Plan, Inc. Medical Necessity Criteria Page 9/14

10 M05.9 Rheumatid arthritis with rheumatid factr, unspecified M06.00 Rheumatid arthritis withut rheumatid factr, unspecified site M Rheumatid arthritis withut rheumatid factr, right shulder M Rheumatid arthritis withut rheumatid factr, left shulder M Rheumatid arthritis withut rheumatid factr, unspecified shulder M Rheumatid arthritis withut rheumatid factr, right elbw M Rheumatid arthritis withut rheumatid factr, left elbw M Rheumatid arthritis withut rheumatid factr, unspecified elbw M Rheumatid arthritis withut rheumatid factr, right wrist M Rheumatid arthritis withut rheumatid factr, left wrist M Rheumatid arthritis withut rheumatid factr, unspecified wrist M Rheumatid arthritis withut rheumatid factr, right hand M Rheumatid arthritis withut rheumatid factr, left hand M Rheumatid arthritis withut rheumatid factr, unspecified hand M Rheumatid arthritis withut rheumatid factr, right hip M Rheumatid arthritis withut rheumatid factr, left hip M Rheumatid arthritis withut rheumatid factr, unspecified hip M Rheumatid arthritis withut rheumatid factr, right knee M Rheumatid arthritis withut rheumatid factr, left knee M Rheumatid arthritis withut rheumatid factr, unspecified knee M Rheumatid arthritis withut rheumatid factr, right ankle and ft M Rheumatid arthritis withut rheumatid factr, left ankle and ft M Rheumatid arthritis withut rheumatid factr, unspecified ankle and ft M06.08 Rheumatid arthritis withut rheumatid factr, vertebrae M06.09 Rheumatid arthritis withut rheumatid factr, multiple sites M06.80 Other specified rheumatid arthritis, unspecified site M Other specified rheumatid arthritis, right shulder M Other specified rheumatid arthritis, left shulder M Other specified rheumatid arthritis, unspecified shulder M Other specified rheumatid arthritis, right elbw M Other specified rheumatid arthritis, left elbw M Other specified rheumatid arthritis, unspecified elbw M Other specified rheumatid arthritis, right wrist M Other specified rheumatid arthritis, left wrist M Other specified rheumatid arthritis, unspecified wrist M Other specified rheumatid arthritis, right hand M Other specified rheumatid arthritis, left hand M Other specified rheumatid arthritis, unspecified hand M Other specified rheumatid arthritis, right hip M Other specified rheumatid arthritis, left hip M Other specified rheumatid arthritis, unspecified hip Mda Health Plan, Inc. Medical Necessity Criteria Page 10/14

11 M Other specified rheumatid arthritis, right knee M Other specified rheumatid arthritis, left knee M Other specified rheumatid arthritis, unspecified knee M Other specified rheumatid arthritis, right ankle and ft M Other specified rheumatid arthritis, left ankle and ft M Other specified rheumatid arthritis, unspecified ankle and ft M06.88 Other specified rheumatid arthritis, vertebrae M06.89 Other specified rheumatid arthritis, multiple sites M06.9 Rheumatid arthritis, unspecified M08.00 Unspecified juvenile rheumatid arthritis f unspecified site M Unspecified juvenile rheumatid arthritis, right shulder M Unspecified juvenile rheumatid arthritis, left shulder M Unspecified juvenile rheumatid arthritis, unspecified shulder M Unspecified juvenile rheumatid arthritis, right elbw M Unspecified juvenile rheumatid arthritis, left elbw M Unspecified juvenile rheumatid arthritis, unspecified elbw M Unspecified juvenile rheumatid arthritis, right wrist M Unspecified juvenile rheumatid arthritis, left wrist M Unspecified juvenile rheumatid arthritis, unspecified wrist M Unspecified juvenile rheumatid arthritis, right hand M Unspecified juvenile rheumatid arthritis, left hand M Unspecified juvenile rheumatid arthritis, unspecified hand M Unspecified juvenile rheumatid arthritis, right hip M Unspecified juvenile rheumatid arthritis, left hip M Unspecified juvenile rheumatid arthritis, unspecified hip M Unspecified juvenile rheumatid arthritis, right knee M Unspecified juvenile rheumatid arthritis, left knee M Unspecified juvenile rheumatid arthritis, unspecified knee M Unspecified juvenile rheumatid arthritis, right ankle and ft M Unspecified juvenile rheumatid arthritis, left ankle and ft M Unspecified juvenile rheumatid arthritis, unspecified ankle and ft M08.08 Unspecified juvenile rheumatid arthritis, vertebrae M08.09 Unspecified juvenile rheumatid arthritis, multiple sites M08.20 Juvenile rheumatid arthritis with systemic nset, unspecified site M Juvenile rheumatid arthritis with systemic nset, right shulder M Juvenile rheumatid arthritis with systemic nset, left shulder M Juvenile rheumatid arthritis with systemic nset, unspecified shulder M Juvenile rheumatid arthritis with systemic nset, right elbw M Juvenile rheumatid arthritis with systemic nset, left elbw M Juvenile rheumatid arthritis with systemic nset, unspecified elbw M Juvenile rheumatid arthritis with systemic nset, right wrist Mda Health Plan, Inc. Medical Necessity Criteria Page 11/14

12 M Juvenile rheumatid arthritis with systemic nset, left wrist M Juvenile rheumatid arthritis with systemic nset, unspecified wrist M Juvenile rheumatid arthritis with systemic nset, right hand M Juvenile rheumatid arthritis with systemic nset, left hand M Juvenile rheumatid arthritis with systemic nset, unspecified hand M Juvenile rheumatid arthritis with systemic nset, right hip M Juvenile rheumatid arthritis with systemic nset, left hip M Juvenile rheumatid arthritis with systemic nset, unspecified hip M Juvenile rheumatid arthritis with systemic nset, right knee M Juvenile rheumatid arthritis with systemic nset, left knee M Juvenile rheumatid arthritis with systemic nset, unspecified knee M Juvenile rheumatid arthritis with systemic nset, right ankle and ft M Juvenile rheumatid arthritis with systemic nset, left ankle and ft M Juvenile rheumatid arthritis with systemic nset, unspecified ankle and ft M08.28 Juvenile rheumatid arthritis with systemic nset, vertebrae M08.29 Juvenile rheumatid arthritis with systemic nset, multiple sites M08.3 Juvenile rheumatid plyarthritis (sernegative) M08.3 Juvenile rheumatid plyarthritis (sernegative) M08.40 Pauciarticular juvenile rheumatid arthritis, unspecified site M08.40 Pauciarticular juvenile rheumatid arthritis, unspecified site M Pauciarticular juvenile rheumatid arthritis, right shulder M Pauciarticular juvenile rheumatid arthritis, left shulder M Pauciarticular juvenile rheumatid arthritis, unspecified shulder M Pauciarticular juvenile rheumatid arthritis, right elbw M Pauciarticular juvenile rheumatid arthritis, left elbw M Pauciarticular juvenile rheumatid arthritis, unspecified elbw M Pauciarticular juvenile rheumatid arthritis, right wrist M Pauciarticular juvenile rheumatid arthritis, left wrist M Pauciarticular juvenile rheumatid arthritis, unspecified wrist M Pauciarticular juvenile rheumatid arthritis, right hand M Pauciarticular juvenile rheumatid arthritis, left hand M Pauciarticular juvenile rheumatid arthritis, unspecified hand M Pauciarticular juvenile rheumatid arthritis, right hip M Pauciarticular juvenile rheumatid arthritis, left hip M Pauciarticular juvenile rheumatid arthritis, unspecified hip M Pauciarticular juvenile rheumatid arthritis, right knee M Pauciarticular juvenile rheumatid arthritis, left knee M Pauciarticular juvenile rheumatid arthritis, unspecified knee M Pauciarticular juvenile rheumatid arthritis, right ankle and ft M Pauciarticular juvenile rheumatid arthritis, left ankle and ft M Pauciarticular juvenile rheumatid arthritis, unspecified ankle and ft Mda Health Plan, Inc. Medical Necessity Criteria Page 12/14

13 M08.48 Pauciarticular juvenile rheumatid arthritis, vertebrae M08.80 Other juvenile arthritis, unspecified site M Other juvenile arthritis, right shulder M Other juvenile arthritis, left shulder M Other juvenile arthritis, unspecified shulder M Other juvenile arthritis, right elbw M Other juvenile arthritis, left elbw M Other juvenile arthritis, unspecified elbw M Other juvenile arthritis, right wrist M Other juvenile arthritis, left wrist M Other juvenile arthritis, unspecified wrist M Other juvenile arthritis, right hand M Other juvenile arthritis, left hand M Other juvenile arthritis, unspecified hand M Other juvenile arthritis, right hip M Other juvenile arthritis, left hip M Other juvenile arthritis, unspecified hip M Other juvenile arthritis, right knee M Other juvenile arthritis, left knee M Other juvenile arthritis, unspecified knee M Other juvenile arthritis, right ankle and ft M Other juvenile arthritis, left ankle and ft M Other juvenile arthritis, unspecified ankle and ft M08.88 Other juvenile arthritis, ther specified site M08.89 Other juvenile arthritis, multiple sites M08.90 Juvenile arthritis, unspecified, unspecified site M Juvenile arthritis, unspecified, right shulder M Juvenile arthritis, unspecified, left shulder M Juvenile arthritis, unspecified, unspecified shulder M Juvenile arthritis, unspecified, right elbw M Juvenile arthritis, unspecified, left elbw M Juvenile arthritis, unspecified, unspecified elbw M Juvenile arthritis, unspecified, right wrist M Juvenile arthritis, unspecified, left wrist M Juvenile arthritis, unspecified, unspecified wrist M Juvenile arthritis, unspecified, right hand M Juvenile arthritis, unspecified, left hand M Juvenile arthritis, unspecified, unspecified hand M Juvenile arthritis, unspecified, right hip M Juvenile arthritis, unspecified, left hip M Juvenile arthritis, unspecified, unspecified hip Mda Health Plan, Inc. Medical Necessity Criteria Page 13/14

14 M Juvenile arthritis, unspecified, right knee M Juvenile arthritis, unspecified, left knee M Juvenile arthritis, unspecified, unspecified knee M Juvenile arthritis, unspecified, right ankle and ft M Juvenile arthritis, unspecified, left ankle and ft M Juvenile arthritis, unspecified, unspecified ankle and ft M08.98 Juvenile arthritis, unspecified, vertebrae M08.99 Juvenile arthritis, unspecified, multiple sites Appendix 2 Centers fr Medicare and Medicaid Services (CMS) Medicare cverage fr utpatient (Part B) drugs is utlined in the Medicare Benefit Plicy Manual (Pub ), Chapter 15, 50 Drugs and Bilgicals. In additin, Natinal Cverage Determinatin (NCD) and Lcal Cverage Determinatins (LCDs) may exist and cmpliance with these plicies is required where applicable. They can be fund at: Additinal indicatins may be cvered at the discretin f the health plan. Medicare Part B Cvered Diagnsis Cdes (applicable t existing NCD/LCD): Jurisdictin(s): N NCD/LCD Dcument (s): L33257 Jurisdictin(s): 5, 8 NCD/LCD Dcument (s): L Medicare Part B Administrative Cntractr (MAC) Jurisdictins Jurisdictin Applicable State/US Territry Cntractr E (1) CA, HI, NV, AS, GU, CNMI Nridian Healthcare Slutins, LLC F (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Nridian Healthcare Slutins, LLC 5 KS, NE, IA, MO Wiscnsin Physicians Service Insurance Crp (WPS) 6 MN, WI, IL Natinal Gvernment Services, Inc. (NGS) H (4 & 7) LA, AR, MS, TX, OK, CO, NM Nvitas Slutins, Inc. 8 MI, IN Wiscnsin Physicians Service Insurance Crp (WPS) N (9) FL, PR, VI First Cast Service Optins, Inc. J (10) TN, GA, AL Cahaba Gvernment Benefit Administratrs, LLC M (11) NC, SC, WV, VA (excluding belw) Palmett GBA, LLC L (12) DE, MD, PA, NJ, DC (includes Arlingtn & Fairfax cunties and the city f Alexandria in VA) K (13 & 14) NY, CT, MA, RI, VT, ME, NH Nvitas Slutins, Inc. Natinal Gvernment Services, Inc. (NGS) 15 KY, OH CGS Administratrs, LLC Mda Health Plan, Inc. Medical Necessity Criteria Page 14/14

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092

Kadcyla (ado-trastuzumab emtansine) Document Number: IC-0092 Kadcyla (ad-trastuzumab emtansine) Dcument Number: IC-0092 Last Review Date: 2/6/2018 Date f Origin: 05/16/2013 Dates Reviewed: 7/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 5/2015, 8/2015,

More information

Actemra (tocilizumab) (Intravenous)

Actemra (tocilizumab) (Intravenous) Actemra (tcilizumab) (Intravenus) Last Review Date: 06/01/2018 Date f Origin: 09/21/2010 Dcument Number: MODA-0002 Dates Reviewed: 12/2010, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,

More information

Mylotarg (gemtuzumab ozogamicin) (Intravenous)

Mylotarg (gemtuzumab ozogamicin) (Intravenous) Myltarg (gemtuzumab zgamicin) (Intravenus) Last Review Date: 09/19/2017 Date f Origin: 09/19/2017 Dates Reviewed: 09/2017 Dcument Number: IC-0320 I. Length f Authrizatin Newly-Diagnsed AML De nv disease

More information

Perjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria

Perjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,

More information

Krystexxa (pegloticase) Document Number: IC-0158

Krystexxa (pegloticase) Document Number: IC-0158 Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length

More information

Soliris (eculizumab) Document Number: MODA-0114

Soliris (eculizumab) Document Number: MODA-0114 Sliris (eculizumab) Dcument Number: MODA-0114 Last Review Date: 9/19/2017 Date f Origin: 06/21/2011 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 03/2014, 06/2014, 09/2014,

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive

More information

Simponi ARIA (golimumab) (Intravenous)

Simponi ARIA (golimumab) (Intravenous) Simponi ARIA (golimumab) (Intravenous) Last Review Date: 10/31/2017 Date of Origin: 09/05/2013 Document Number: MODA-0176 Dates Reviewed: 12/2013, 8/2014, 3/2015, 6/2015, 9/2015, 12/2015, 3/2016, 6/2016,

More information

Eylea (aflibercept) Document Number: IC-0026

Eylea (aflibercept) Document Number: IC-0026 Eylea (aflibercept) Document Number: IC-0026 Last Review Date: 3/1/2018 Date of Origin: 02/07/2013 Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015,

More information

Intravitreal Avastin (Bevacizumab)

Intravitreal Avastin (Bevacizumab) Intravitreal Avastin (Bevacizumab) Date of Origin: 10/18/2018 Last Review Date: 10/18/2018 Effective Date: 10/18/2018 Dates Reviewed: 10/2018 Developed By: Medical Criteria Committee I. Length of Authorization

More information

Ilaris (canakinumab) (Subcutaneous)

Ilaris (canakinumab) (Subcutaneous) Ilaris (canakinumab) (Subcutaneous) Last Review Date: 08/02/2018 Date of Origin: 11/07/2013 Dates Reviewed: 08/2014, 07/2015, 07/2016, 10/2016, 10/2017, 08/2018 Document Number: IC-0177 I. Length of Authorization

More information

Velcade (bortezomib) Document Number: IC-0137

Velcade (bortezomib) Document Number: IC-0137 Velcade (bortezomib) Document Number: IC-0137 Last Review Date: 11/21/2017 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014,

More information

Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014,

Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, Perjeta (pertuzumab) Last Review Date: 5/30/2017 Date of Origin: 11/01/2012 Document Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014,

More information

Sandostatin LAR (octreotide suspension) Document Number: IC-0111

Sandostatin LAR (octreotide suspension) Document Number: IC-0111 Sandstatin LAR (ctretide suspensin) Dcument Number: IC-0111 Last Review Date: 02/06/2018 Date f Origin: 06/21/2011 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013,

More information

Imfinzi (durvalumab) (Intravenous)

Imfinzi (durvalumab) (Intravenous) Imfinzi (durvalumab) (Intravenous) Last Review Date: 09/05/2018 Date of Origin: 05/30/2017 Dates Reviewed: 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018 Document Number: IC-0301 I. Length of Authorization

More information

Tecentriq (atezolizumab) (Intravenous)

Tecentriq (atezolizumab) (Intravenous) Tecentriq (atezolizumab) (Intravenous) Last Review Date: 06/01/2018 Date of Origin: 06/28/2016 Document Number: IC-0278 Dates Reviewed: 06/2016, 08/2016, 10/2016, 02/2017, 04/2017, 08/2017, 11/2017, 02/2018,

More information

Abraxane (paclitaxel protein-bound particles) (Intravenous)

Abraxane (paclitaxel protein-bound particles) (Intravenous) Abraxane (paclitaxel prtein-bund particles) (Intravenus) Last Review Date: 5/30/2017 Date f Origin: 10/17/2008 Dcument Number: IC-0001 Dates Reviewed: 06/2009, 12/2009, 07/2010, 09/2010, 12/2010, 03/2011,

More information

Yescarta (axicabtagene ciloleucel) (Intravenous)

Yescarta (axicabtagene ciloleucel) (Intravenous) Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr

More information

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,

More information

Cyramza (ramucirumab) (Intravenous)

Cyramza (ramucirumab) (Intravenous) Cyramza (ramucirumab) (Intravenous) Document Number: IC 0199 Last Review Date: 5/1/2018 Date of Origin: 06/24/2014 Dates Reviewed: 09/2014, 01/2015, 05/2015, 11/2015, 04/2016, 08/2016, 11/2016, 05/2017,

More information

Document Number: IC I. Length of Authorization. Dosing Limits

Document Number: IC I. Length of Authorization. Dosing Limits Hyaluronic Acid Derivatives: Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz/Supartz FX, Synojoynt, Synvisc, & Synvisc-One, TriVisc, Visco-3 (Intra-articular)

More information

SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune globulin SQ)

SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune globulin SQ) SCIG: Hizentra, Gammagard Liquid, Gamunex -C, Gammaked, Hyqvia, Cuvitru (immune glbulin SQ) Dcument Number: IC-0059 Last Review Date: 04/03/2018 Date f Origin: 7/20/2010 Dates Reviewed: 9/2010, 12/2010,

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,

More information

Soliris (eculizumab) (Intravenous)

Soliris (eculizumab) (Intravenous) Sliris (eculizumab) (Intravenus) Last Review Date: 02/04/2019 Date f Origin: 06/21/2011 Dcument Number: MODA-0114 Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 03/2014,

More information

Yervoy (ipilmumab) Last Review Date: 03/25/2014 Date of Origin: 11/28/2011. Prior Auth Available: Post-Service Edit:

Yervoy (ipilmumab) Last Review Date: 03/25/2014 Date of Origin: 11/28/2011. Prior Auth Available: Post-Service Edit: Yervoy (ipilmumab) Date of Origin: 11/28/2011 Prior Auth Available: Post-Service Edit: Dates Reviewed: 12/13/2011, 03/2012, 06/19/2012, 09/06/2012, 12/06/2012, 05/16/2013, 06/06/2013, 09/05/2013, 12/05/2013,

More information

Must be used as initial treatment as a single agent with sequential chemoradiation

Must be used as initial treatment as a single agent with sequential chemoradiation Erbitux (cetuximab) Dcument Number: IC-0038 Last Review Date: 11/21/2017 Date f Origin: 12/22/2009 Dates Reviewed: 07/2010, 09/2010, 12/2010, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012,

More information

Subject: Abatacept (Orencia ) Injection and Infusion

Subject: Abatacept (Orencia ) Injection and Infusion 09-J0000-67 Original Effective Date: 06/15/07 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Abatacept (Orencia ) Injectin and Infusin THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

Rituxan (rituximab) Document Number: IC-0109

Rituxan (rituximab) Document Number: IC-0109 Rituxan (rituximab) Dcument Number: IC-0109 Last Review Date: 10/31/2017 Date f Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,

More information

Cimzia (certolizumab pegol) (Subcutaneous)

Cimzia (certolizumab pegol) (Subcutaneous) Cimzia (certolizumab pegol) (Subcutaneous) Last Review Date: 06/01/2018 Date of Origin: 11/28/2011 Document Number: IC-0028 Dates Reviewed: 12/2011, 11/2012, 11/2013, 12/2013, 08/2014, 03/2015, 06/2015,

More information

Renflexis (infliximab-abda)

Renflexis (infliximab-abda) Renflexis (infliximab-abda) Last Review Date: 04/25/2017 Date of Origin: 04/25/2017 Dates Reviewed: 04/2017 Document Number: MODA-0300 I. Length of Authorization Coverage is provided for 6 months and may

More information

New Exception Status Benefits

New Exception Status Benefits FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria

More information

Trelstar (triptorelin) (Intramuscular)

Trelstar (triptorelin) (Intramuscular) Trelstar (triptorelin) (Intramuscular) Last Review Date: 02/06/2018 Date of Origin: 11/28/2011 Document Number: IC-0131 Dates Reviewed: 12/2011, 03/2012, 06/19/2012, 09/2012, 12/2012, 03/2013, 06/2013,

More information

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Colony Stimulating Factors: Zarxio (filgrastim sndz) (Subcutaneous/Intravenous) Document Number: IC 0245 Last Review Date: 5/1/2018 Date of Origin: 03/31/2015 Dates Reviewed: 03/2015, 05/2015, 08/2015,

More information

Stelara (ustekinumab)

Stelara (ustekinumab) Stelara (ustekinumab) Last Review Date: 03/01/2018 Date of Origin: 02/15/2011 Document Number: MODA-0117 Dates Reviewed: 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 03/2013, 06/2013,

More information

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses

More information

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous)

Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Colony Stimulating Factors: Nivestym (filgrastim-aafi) (Subcutaneous/Intravenous) Document Number: MODA-0375 Last Review Date: 08/06/2018 Date of Origin: 08/06/2018 Dates Reviewed: 08/2018 I. Length of

More information

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit (epoetin alfa) (Subcutaneous/Intravenous)

Erythropoiesis Stimulating Agents (ESAs): Epogen/Procrit (epoetin alfa) (Subcutaneous/Intravenous) (Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.81 Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth

More information

Trelstar Depot (triptorelin)

Trelstar Depot (triptorelin) Dates Reviewed: 12/13/2011, 03/2012, 06/19/2012, 09/06/2012, 12/06/2012, 03/07/2013, 06/06/2013, Date of Origin: 11/28/2011 09/05/2013, 12/05/2013, 03/25/2014 Prior Auth Available: Post-service edit: The

More information

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17 Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial

More information

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals (Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Retaking NPTE

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Retaking NPTE The table below lists the requirements for retaking the National Physical Therapy Exam (NPTE) for each jurisdiction. Summary Number of attempts on NPTE limited? 16 27 Number of attempts allowed before

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access Each licensing authority indicates the level of direct access allowed in the jurisdiction and the type of limitations that apply to this access. There are two tables: Types and Limits Referrals TYPES AND

More information

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) (Subcutaneous/Intravenous) *NON DIALYSIS* Document Number: IC 0242 Last Review Date: 05/01/2018 Date of Origin: 10/17/2008 Dates Reviewed:

More information

Alimta (pemetrexed) Document Number: IC 0007

Alimta (pemetrexed) Document Number: IC 0007 Alimta (pemetrexed) Document Number: IC 0007 Last Review Date: 05/01/2018 Date of Origin: 07/20/2010 Dates Reviewed: 09/2010, 12/2010, 03/2011, 06/2011,0 9/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012,

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access Each licensing authority indicates the level of direct access allowed in the jurisdiction and the type of limitations that apply to this access. There are two tables: Types and Limits Referrals TYPES AND

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745 Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES

More information

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Request for Prior Authorization for Click here to enter text. Website Form   Submit request via: Fax Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus

More information

Financial Impact of Lung Cancer in West Virginia

Financial Impact of Lung Cancer in West Virginia Financial Impact of Lung Cancer in West Virginia John Deskins, Ph.D. Christiadi, Ph.D. Sara Harper November 2018 Bureau of Business & Economic Research College of Business & Economics West Virginia University

More information

Workforce Data The American Board of Pediatrics

Workforce Data The American Board of Pediatrics Workforce Data 2009-2010 The American Board of Pediatrics Caution. Before using this report as a resource, please read the information below! Please use caution when comparing data in this version of the

More information

2016 COMMUNITY SURVEY

2016 COMMUNITY SURVEY 1 Epilepsy Innovation Institute (Ei ) 016 COMMUNITY SURVEY INTRODUCTION From September 8th to November 9th, 016, epilepsy.com hosted a survey that asked the community the following: What are the aspects

More information

Inflectra (infliximab-dyyb) Document Number: MODA-0275

Inflectra (infliximab-dyyb) Document Number: MODA-0275 Inflectra (infliximab-dyyb) Document Number: MODA-0275 Last Review Date: 09/19/2017 Date of Origin: 04/26/2016 Dates Reviewed: 04/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017 I. Length of Authorization

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date: Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. This Cverage Plicy applies t Individual Health Insurance Marketplace benefit plans nly. Immunlgical Agents Bilgical Respnse Mdifier-Tumr Necrsis Factr (TNF) Inhibitrs: Enbrel (etanercept fr subcutaneus

More information

Orencia (abatacept) DRUG.00040

Orencia (abatacept) DRUG.00040 Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

Clinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:

Clinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date: Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal

More information

Referral Criteria: Inflammation of the Spine Feb

Referral Criteria: Inflammation of the Spine Feb Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated PTs and PTAs

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated PTs and PTAs PT Requirements for Licensure Summary: Number of Jurisdictions that Require: Educational Credentials Review 50 from a program equivalent to CAPTE 37 Eligibility to practice in the country in which education

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Prolia /Xgeva (denosumab) Document Number: IC-0098

Prolia /Xgeva (denosumab) Document Number: IC-0098 / (denosumab) Document Number: IC-0098 Last Review Date: 5/30/2017 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 03/2014, 06/2014, 09/2014, 12/2014,

More information

RECOVERY SUPPORT SERVICES IN STATES

RECOVERY SUPPORT SERVICES IN STATES RECOVERY SUPPORT SERVICES IN STATES An analysis of State recovery support services using the 16 17 Substance Abuse Block Grant (SABG) Behavioral Health Assessment and Plan THIS PROJECT IS BEING SUPPORTED

More information

Folotyn (pralatrexate)

Folotyn (pralatrexate) Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated Physical Therapists

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Foreign Educated Physical Therapists Requirements for Licensure Summary: Number of Jurisdictions that Require: Educational Credentials Review 50 Graduation from a program equivalent to CAPTE 37 Eligibility to practice in the country in which

More information

BY-STATE MENTAL HEALTH SERVICES AND EXPENDITURES IN MEDICAID, 1999

BY-STATE MENTAL HEALTH SERVICES AND EXPENDITURES IN MEDICAID, 1999 STATE-BY BY-STATE MENTAL HEALTH SERVICES AND EXPENDITURES IN MEDICAID, 1999 James Verdier,, Ann Cherlow,, and Allison Barrett Mathematica Policy Research, Inc. Jeffrey Buck and Judith Teich Substance Abuse

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Direct Access Each licensing authority indicates the level of direct access allowed in the jurisdiction and the type of limitations that apply to this access. There are three tables: Types and Limits Specific Limits

More information

USA National Mental Healthcare Nonprofit Exempt Organization Financial Analysis as of December 14, 2015 January 24, 2016 ANSA-H2

USA National Mental Healthcare Nonprofit Exempt Organization Financial Analysis as of December 14, 2015 January 24, 2016 ANSA-H2 USA National Mental Healthcare Nonprofit Exempt Organization Financial Analysis as of December 14, 2015 January 24, 2016 ANSA-H2 Prepared by David Yoo, HanaSoul Consulting, Omaha, Nebraska dcyoo@cox.net

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

MBP 40.0 Orencia IV (abatacept)- Updated policy

MBP 40.0 Orencia IV (abatacept)- Updated policy What s New Medical Pharmaceutical Plicy Nvember 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated plicy Fr Treatment f Rheumatid Arthritis: Must

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: License Renewal. License Renewal on Birthdays

Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: License Renewal. License Renewal on Birthdays The table below lists information on the term and renewal date for each jurisdiction. Summary License Term 1 26 2 Renewal Date One date 31 Birthdays 6 Half in even years 4 4 License Term AL AK AZ AR CA

More information

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form   Submit request via: Fax Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Enbrel (etanercept) require a prior

More information

Benepali (etanercept): Brief training on additional Risk Minimisation Measures

Benepali (etanercept): Brief training on additional Risk Minimisation Measures Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Tocilizumab (Actemra) Reference Number: CP.PHAR.263 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Actemra) Reference Number: CP.PHAR.263 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Opdivo (nivolumab) (Intravenous)

Opdivo (nivolumab) (Intravenous) Opdiv (nivlumab) (Intravenus) Last Review Date: 1/03/2018 Date f Origin: 01/06/2015 Dcument Number: IC-0226 Dates Reviewed: 03/2015, 07/2015, 10/2015, 11/2015, 02/2016, 05/2016, 08/2016, 10/2016, 11/2016,

More information

High Performance Network Quality Criteria for Designation

High Performance Network Quality Criteria for Designation Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Actemra) Reference Number: HIM.PA.SP32 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at

More information

The Affordable Care Act and HIV: What are the Implications?

The Affordable Care Act and HIV: What are the Implications? The Affordable Care Act and HIV: What are the Implications? 2013 National Black AIDS Institute Webinar Series September 18, 2013 Jen Kates, Kaiser Family Foundation The Challenge Figure 1 30 years into

More information

Arkansas Prescription Monitoring Program

Arkansas Prescription Monitoring Program Arkansas Prescription Monitoring Program FY 2017 Second Quarter Report October December 2016 Arkansas Prescription Monitoring Program Quarterly Report October December, Fiscal year 2017 Act 304 of 2011

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

How to Get Paid for Doing EBD

How to Get Paid for Doing EBD How to Get Paid for Doing EBD Robert D. Compton, DDS President Robert Compton, DDS Executive Director DentaQuest Institute Disclosure DentaQuest Institute President DentaQuest Benefits Senior VP & CDO

More information

CHILDHOOD ALLERGIES IN AMERICA

CHILDHOOD ALLERGIES IN AMERICA CHILDHOOD ALLERGIES IN AMERICA Severe Allergic Reactions Causing More Emergency Room Visits for U.S. Children PUBLISHED MARCH 13, 2018 ( 2 ) EXECUTIVE SUMMARY In this report, the Blue Cross Blue Shield

More information

State of California Department of Justice. Bureau of Narcotic Enforcement

State of California Department of Justice. Bureau of Narcotic Enforcement State of California Department of Justice Bureau of Narcotic Enforcement Prescription Drugs in the U.S. At least half of all Americans take one prescription drug regularly, with one in six taking three

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Guideline for the Prescribing of Biologic Therapy in adult patients ( 16 years) with active and progressive Psoriatic Arthritis (PsA) within NHS Fife

Guideline for the Prescribing of Biologic Therapy in adult patients ( 16 years) with active and progressive Psoriatic Arthritis (PsA) within NHS Fife Guideline fr the Prescribing f Bilgic Therapy in adult patients ( 16 years) with active and prgressive Psriatic Arthritis (PsA) within NHS Fife Dcument Number & Versin Versin 1.0 Date Ratified: 20/12/16

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 6/18 Pharmacy- Frmulary 2 x Date f Origin: 11/07 Immune Glbulins Intravenus: Carimune NF, Flebgamma,

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

Evidence-Based Policymaking: Investing in Programs that Work

Evidence-Based Policymaking: Investing in Programs that Work Evidence-Based Policymaking: Investing in Programs that Work August 4, 2015 The Policy Challenge Though policymakers want to make the best choices, the process often relies on inertia and anecdote Very

More information